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I.   INTRODUCTION 
In 1977, disco flairs were all the rage, quarterback Tom Brady was only just 
born, and investors had the option to buy stock in a new company called Apple, 
                                                          
 J.D./M.P.A. candidate 2015, Cleveland-Marshall College of Law and Cleveland State 
University; B.A. Baldwin-Wallace College, 2011. Lauren would like to thank her parents Ron 
and Kathy Orrico, her sister Lindsay Orrico, and her boyfriend Andrew Jenkins for their 
patience, love, and support. She would also like to thank her Note advisor Carolyn Broering-
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which was incorporated in January of that year.1 Economic and spending 
considerations were also at play in the 1970’s as President Jimmy Carter attempted 
to fight unemployment by allowing the federal deficit to swell and establishing job 
programs.2 Finally, 1977 saw the Food and Drug Administration (FDA) issue notices 
announcing its intent to withdraw approval of the use of certain growth-promoting 
antibiotics in animals raised for food (commonly referred to as “food animals”).3 The 
FDA found that broad use of these antibiotics led to the development of antibiotic-
resistant bacteria.4 These bacteria were deemed detrimental to human health because 
they caused antibiotic-resistant infections, which were difficult to treat.5 Thirty-five 
years later, few people would suggest giving those bell-bottoms another spin or 
debate the success of Apple, but the threat of antibiotic resistance is growing ever 
larger and costing Americans billions of dollars each year.6 
Although government policies have evolved in the last thirty-five years, 
Americans still understand the importance of balancing costs and benefits, and of 
making sacrifices now to ensure a safe world for future generations. Antibiotic-
resistant bacteria threaten the health of current and future generations if their effects 
are not curbed soon.7 According to the Infectious Diseases Society of America 
(IDSA), just one antibiotic-resistant organism, Methicillin Resistant Staphylococcus 
Aureus (MRSA),8 kills more Americans every year than emphysema, HIV/AIDS, 
                                                          
 1 See Frequently Asked Questions, Apple Corporate Information, APPLE, http://investor. 
apple.com/faq.cfm?FaqSetID=6 (last visited Mar. 8, 2014) (for information regarding Apple); 
see also Tom Brady, ESPN, http://espn.go.com/nfl/player/_/id/ 2330/tom-brady (last visited 
Mar. 8, 2014) (for information on Tom Brady).  
 2 Ann Mari May, Fiscal Policy, Monetary Policy and The Carter Presidency, 23 
Presidential Studies Quarterly 699 (1993), available at http://digitalcommons.unl.edu/cgi/ 
viewcontent.cgi?article=1033&context =econfacpub.  
 3 Natural Res. Def. Council, Inc. v. U.S. Food & Drug Admin., 11 CIV. 3562 THK, 2012 
WL 983544 (S.D.N.Y. Mar. 22, 2012).  
 4 Id. at ¶¶ 12. For clarity, the reader should note that an antibiotic is a type of 
antimicrobial drug. While antimicrobial resistance is also a concern, this Note uses the term 
“antibiotic” since animal feed largely contains antibiotics as opposed to other types of 
antimicrobials. For the purposes of this Note, the two terms can be used interchangeably. The 
reader should also note that the terms “antibiotic-resistant bacteria” and “antibiotic-resistant 
infections” are related, but not completely synonymous. Antibiotic-resistant bacteria are the 
organisms that cause antibiotic-resistant infections, which in turn make humans ill. See infra 
Part II(B).  
 5 Natural Res. Def. Council, Inc. v. U.S. Food & Drug Admin., 11 CIV. 3562 THK, 2012 
WL 983544 (S.D.N.Y. Mar. 22, 2012).  
 6 CTRS. FOR DISEASE CONTROL & PREVENTION, ANTIBIOTIC RESISTANCE THREATS IN THE 
UNITED STATES (2013), available at http://www.cdc.gov/media/releases/2013/p0916-
untreatable.html. 
 7 U.S. DEP’T OF HEALTH & HUMAN SERVICES, FOOD & DRUG ADMIN., GUIDANCE FOR 
INDUSTRY #209: THE JUDICIOUS USE OF MEDICALLY IMPORTANT ANTIMICROBIAL DRUGS IN 
FOOD-PRODUCING ANIMALS (2012), available at http://www.FDA.gov/downloads/animal 
veterinary/guidancecomplianceenforcement/guidanceforindustry/ucm2 16936.pdf  [hereinafter 
GUIDANCE #209].  
 8 MRSA is a “staph” germ that many of us carry around daily without falling ill. NAT’L 
CTR. FOR BIOTECHNOLOGY INFO., NAT’L LIBRARY OF MED., NAT’L INST. OF HEALTH, MRSA 
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Parkinson’s disease, and homicide combined.9 The economic cost of antibiotic-
resistant infections to the United States health care system is twenty-one billion to 
thirty-four billion dollars each year—along with an additional eight million hospital 
days for patients.10 These economic costs, along with the social costs of 
environmental degradation, animal cruelty, and adverse health effects, make cost-
effective policy initiatives crucial for preserving the health and well-being of our 
society.11 
The spread of antibiotic-resistant infections is finally being widely recognized by 
medical professionals as a serious threat that can be slowed through proper policy.12 
Resistant bacteria multiply when antibiotics are overused.13 As around half of all 
antibiotics used in the United States are given to animals for various reasons, 
overuse in food animals is a major cause of this problem.14 Numerous studies have 
linked the wide-spread use of antibiotics in animal feed to the development of 
antibiotic resistance in humans.15 Antibiotic resistance has led to massive food 
recalls and a higher prevalence of drug-resistant infections, allergies, and 
autoimmune diseases in children.16 However, current legislation fails to address the 
problem, preferring instead to defer responsibility to the hesitant FDA17 
The FDA, although recognizing the health concern as far back as 1977, has 
refused to ban the use of antibiotics for disease prevention and growth promotion in 
food animals.18 However, a recent U.S. District Court ruling brought subtherapeutic 
use back into the public spotlight when it ordered the FDA to follow through on 
proceedings initiated in 1977 to ban the subtherapeutic use of certain antibiotics in 
                                                          
(2012), available at http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004520/. However, 
individuals who have weakened immune systems or other health issues are susceptible to the 
diseases effects, most notably: severe chest pain, fever and chills, wounds that do not heal, and 
death. As MRSA is commonly spread through skin-to-skin contact, and is now resistant to 
first-line antibiotics, the disease has become a serious problem in hospitals and long-term care 
facilities.  
 9 Facts About Antibiotic Resistance, INFECTIOUS DISEASES SOC’Y OF AM., http://www. 
idsociety.org/IDSA/Site_Map/Topics_of_Interest/Antimicrobial_Resistance/Public_Policy/Fa
cts_about_Antibiotic_Resistance.aspx (last visited Mar. 3, 2013).     
 10 Id.   
 11 See infra Part II(C)(2). 
 12 See INFECTIOUS DISEASES SOC’Y OF AM., supra note 9. 
 13 STUART B. LEVY, THE ANTIBIOTIC PARADOX: HOW MIRACLE DRUGS ARE DESTROYING 
THE MIRACLE 14142 (1992). While the overuse of antibiotics by humans themselves also 
contributes to the problem, such a discussion is beyond the scope of this Note.  
 14 Id. at 13738.   
 15  See LEVY, supra note 13. 
 16 See infra Part II(B).   
 17 See infra Part III(A)(B).  
 18 Natural Res. Def. Council, Inc. v. U.S. Food & Drug Admin., 11 CIV. 3562 THK, 2012 
WL 983544 (S.D.N.Y. Mar. 22, 2012).   
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livestock.19 The FDA has resisted, however, pointed out the detriment that an 
outright ban would have on our modern factory farming system and preferring to 
allow large farms to solve the problem them.20 The FDA appealed the District 
Court’s ruling, and the Second Circuit reversed the decision in July 2014.21 While 
this reversal may mean the FDA is not legally obligated to continue withdrawal 
proceedings, the case has brought an important health threat to the public’s attention 
and has the potential to serve as a foundation for a reform movement. 
New legislation is needed to reduce both the economic and social costs of 
subtherapeutic antibiotic use—taking into consideration the needs of farmers and the 
cost to the public of more expensive food. Even if the ruling had not been reversed, 
the ruling had several limitations. The ruling did not specify how the FDA must 
tackle the problem and only applied to a limited class of antibiotics.22 Accordingly, 
the economic and social costs of antibiotic resistance must be combated through 
congressionally mandated standards and requirements, mandatory FDA withdrawal 
of subtherapeutic antibiotic use in food animals, and procedural enforcement through 
the courts. These policies should be phased in and should consider costs to farmers 
and to the public. 
Section II of this Note will provide background on the practices of the United 
States farming system, which fosters the creation of antibiotic-resistant bacteria. This 
section will also provide background on the detrimental effects that antibiotic 
resistance has on human health and will briefly describe the legal history of food and 
drug regulations. After establishing an informational foundation, Part III will 
elaborate on current laws and describe the legal authority of key players, before 
pointing out the shortcomings in current animal feed policy and recommending the 
development of further regulation in this area. Additionally, Part III will propose 
new legislation to address social and economic costs, while also addressing the 
needs of farmers and meat consumers. This Note proposes a three-tiered approach 
for tackling the problem of antibiotic resistance based on congressional legislation, 
mandatory FDA standards, and proper court enforcement. Finally, this Note will 
conclude with a restatement of the essential issues and the way in which the 
proposed legislation will alleviate those problems. 
 
                                                          
 19 Id. at ¶ 20.  
 20 Id. at ¶¶ 11, 13. The opinion denying the FDA’s request for a time extension provides 
that:  
The Government contends that it will suffer irreparable injury if a stay is not granted 
because the significant resources the FDA will be required to expend in order to 
commence withdrawal proceedings will “compromise FDA's ability to pursue its 
goals with respect to antimicrobial resistance and animal drug licensing by diverting 
resources away from those programs… But the Government has not demonstrated that 
compliance would seriously threaten its mission or operations. Rather, it asserts that 
the diversion of resources will “compromise” the FDA's pursuit of goals relating to 
antimicrobial resistance. 
Id. 
 21 Natural Resources Defense Council, Inc. v. U.S. Food & Drug Admin., 2d Cir. No. 12-
2106-CV L, 2014 WL 3636283 (July 24, 20140). 
 22 11 CIV. 3562 THK, 2012 WL 983544 at ¶ 20.   
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II.  BACKGROUND 
    Subtherapeutic antibiotic use23 is necessary due to the existence of large factory 
farms, which keep profits high and meat prices low.24 Factory farms pack a multitude 
of animals into small spaces where disease can spread quickly.25 These close 
conditions make preventative disease treatment the only practical way to prevent 
mass epidemics.26 Unfortunately, this practice has the adverse effect of creating 
antibiotic super bugs, which spread to other animals, the earth, and humans.27 The 
federal government has attempted to ensure meat safety through legislation, the 
creation of executive agencies, and enforcement in the courts.28 These efforts have 
fallen short. 
A.  Factory Farming 
The vast majority of food animals are raised on factory farms.29 Between 2002 
and 2007, many small to medium sized farms gave way to massive factory farms,30 
largely due to a lack of antitrust and environmental regulations, as well as indirect 
subsidies to the farming industry.31 Factory farms enclose high concentrations of 
animals in small areas and unsanitary conditions in order to keep food production 
costs low and profits high.32 These cramped conditions are ripe for bacterial 
epidemics because disease can easily spread from animal to animal.33 For these 
                                                          
 23 See infra Part II(B).   
 24 Amy R. Sapkota et al., What Do We Feed to Food-Production Animals? A Review of 
Animal Feed Ingredients and Their Potential Impacts on Human Health, 115 ENVTL. HEALTH 
PERSP.  663, 663 (2007).   
 25 Id.   
 26 Id.   
 27 See infra Part II(B).   
 28 Robert Longley, The U.S. Food Safety System – A Case of Shared Government 
Responsibilities, USA TODAY (Sept. 20, 2013), http://usgovinfo.about.com/od/consumer 
awareness /a/The-Us-Food-Safety-System.htm.   
 29 See Sapkota, supra note 24.   
 30 Id.    
 31 Factory Farm Nation - How America Turned Its Livestock Farms into Factories, FOOD 
& WATER WATCH (Nov. 2010), http://www.factoryfarmmap.org/wp-content/uploads/2010/11/ 
FactoryFarmNation-web.pdf. Farm policy encouraged over-production of crops used in 
livestock feed, which artificially depressed the price of feed and indirectly subsidized factory 
farms. Additionally, unchecked mergers and acquisitions between the largest operations led to 
massive industry consolidation and made it more difficult for small or family farms to 
compete. Finally, the lack of environmental rules, the lack of animal rights legislation, and lax 
enforcement allowed farms to expand easily. Id.  
 32 Factory Farm Definition, Merriam Webster, http://www.merriam-webster.com/ 
dictionary/factory%20farm (last visited Jan. 14, 2013).  
 
 33 Henrik C. Wegener, Antibiotics in Animal Feed and Their Role in Resistance 
Development, 6 CURRENT OP. MICROBIOLOGY 439, 439 (2003). 
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reasons, the industry faces a fundamental problem: preventing the spread of disease 
among animals kept in close quarters. 
During the 1950s, the food animal industry began experimenting with 
“nutritional factors” aimed at increasing animal growth and soon discovered that low 
doses of antibiotics increased growth.34 As the full implications of broad antibiotic 
use remained unknown in the 1950s,35 antibiotics were classified as “nutritional” and 
premixed into food without a prescription at low, subtherapeutic levels.36 
Subtherapeutic doses are generally about ten to one hundred times lower than 
therapeutic doses, are prescribed over a longer period of time, and are not directed 
against a particular microorganism.37 Instead, subtherapeutic doses broadly protect 
against infection and promote growth so that animals can be slaughtered faster.38 
Today, in addition to antibiotics, premixed animal feed may contain hormones, 
animal waste products, and parts of animals not fit for human consumption.39 The 
amount of antibiotics present in animal feed has steadily increased to almost 
therapeutic levels, as the food animals build up resistance to the lower doses.40 
Antibiotic resistance has been scientifically linked to across-the-board usage of 
subtherapeutic levels of antibiotics in food animals.41 
                                                          
 34 See LEVY, supra note 13, at 13738. The reason antibiotics increase growth is unknown. 
Some believe that antibiotics have a hidden nutritional value, such as the ability to metabolize 
energy more efficiently; however, the nutritional value theory has been largely discredited. 
The most popular theory is that antibiotics either suppress the growth of certain bacteria that 
compete for needed nutrients, or that antibiotics inhibit production of proteins involved in 
adhesion and bacterial colonization of the intestinal tract. This allows animals to gain the full 
nutritional value of their feed but interferes with their normal processes which could have 
unknown adverse effects. Id.   
 35 Id.   
 
 36 See id. at 137.   
 
 37 See id. at 13738.   
 
 38 Id.   
 
 39 Nicholas D. Kristof, Arsenic in Our Chicken?, N.Y. TIMES (April 4, 2012), 
http://www.nytimes.com/2012/04/05/opinion/kristof-arsenic-in-our-chicken.html? 
partner=rssnyt&emc=rss. While testing for antibiotics in poultry raised on factory farms, 
researchers also found arsenic, caffeine, a banned class of antibiotics, the active antihistamine 
in Benadryl, the active ingredient in Tylenol, and an antidepressant, which is the active 
ingredient in Prozac. Id. 
 40 See LEVY, supra note 13, at 142. In the 1950s, 510 parts per million of tetracycline 
were effective to increase growth and prevent infection. Today 50200 parts per million are 
used to elicit the same effect. Additionally, multiple resistances can result from chronic use of 
one antibiotic. These trends seem to indicate that doses will eventually reach almost 
therapeutic levels, and soon higher doses or new antibiotics will be needed to treat animals 
who are actually sick. See id. at 14243. 
 41 See GUIDANCE #209, supra note 7, at 13. 
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B.  The Current Health Threat: Antibiotic Resistance 
Subtherapeutic antibiotic use in food animals greatly increases the presence of 
antibiotic-resistant bacteria in those animals. Antibiotics are drugs used to treat 
infections caused by bacteria.42 Although antibiotics are a great asset for treating 
illnesses, overuse leads to a phenomenon known as antibiotic resistance.43 Antibiotic 
resistance can develop in humans or animals; however, since the vast majority of 
antibiotics are given to food animals, their bodies are the main breeding ground for 
antibiotic-resistant bacteria.44 Animals’ bodies contain both bacteria that can be 
treated by antibiotics and bacteria that have, through random chance, genetically 
mutated so that antibiotics are ineffective against them.45 The latter type is known as 
antibiotic-resistant bacteria.46  
There is a positive correlation between the production of antibiotic-resistant 
bacteria and antibiotic use.47 When a food animal is given an antibiotic, the antibiotic 
kills off the non-resistant bacteria and the stronger, antibiotic-resistant bacteria 
remain.48 Once their weaker competition has been eliminated, these resistant bacteria 
have a perfect breeding ground in which to multiply.49 Bacteria’s rapid 
multiplication and high mutation rates are heightened by a bacteria free area, leading 
to increases in the antibiotic-resistant presence.50 Tetracyclines, one type of 
antibiotic most commonly used in animal feed, can affect a large variety of bacteria 
and select for resistance to themselves and other antibiotics.51 When food animals are 
                                                          
 42 An antibiotic is a type of antimicrobial drug. According to the FDA:  
Antimicrobial drugs are used to treat infections caused by microorganisms. The term 
“antimicrobial” refers broadly to drugs with activity against a variety of 
microorganisms, including bacteria, viruses, fungi, and parasites (such as malaria). 
The term “antibacterial” refers to drugs with activity against bacteria in particular. 
Another term commonly used to describe an antibacterial drug is “antibiotic.”  This 
term refers to a natural compound produced by a fungus or another microorganism 
that kills bacteria that cause disease in humans or animals. Some antibacterial drugs 
are synthetic compounds; i.e., they are not produced by microorganisms. Though 
these do not meet the technical definition of antibiotics, they are referred to as 
antibiotics in common usage. 
Antibiotic Resistance and the Use of Antibiotics in Animal Agriculture: Hearing Before the 
Subcomm. on Health of the H. Comm. on Energy and Commerce, 111th Cong. 33 (2010) 
(statement of Joshua M. Sharfstein, Principal Deputy Comm’r, Food & Drug Admin), 
http://www.fda.gov/NewsEvents/Testimony/ucm219015.htm.  
 43 Id. at 3435. 
 44 See LEVY, supra note 13, at 14041. 
 45 See id.   
 46 See id. at 141. 
 47 See id. at 142. 
 48 See id. at 140. 
 49 See id. 
 50 See id. at 14041. 
 51 See id. at 143. 
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regularly given preventative doses of antibiotics, the opportunities for harmless 
bacteria to mutate into antibiotic-resistant bacteria are amplified.52 
Antibiotic-resistant bacteria are transferred from food animals to humans in 
several ways.  The most obvious transfer occurs during human consumption of food 
animals containing antibiotic-resistant bacteria.53 Past Salmonella and E. coli 
outbreaks provide evidence of animal to human transmission through consumption.54 
During these outbreaks, massive distributions of infected meat led to large food 
recalls, several deaths, and many more illnesses which were difficult to treat.55 
Salmonella is a common infection in animals that was largely treatable with 
antibiotics prior to 1970.56 However, the Salmonella strains that are prevalent today 
are often incapable of being treated with the normal antibiotic treatment.57 
Salmonella is now largely resistant to two to five antibiotics, depending on the 
strain, and once the bacteria get into a human’s bloodstream and multiply, the 
bacteria can cause high fevers, diarrhea, and death.58 Bacteria such as Salmonella, 
when transferred to humans through the consumption of meat, can cause irreparable 
harm.59 
Antibiotic-resistant bacteria can also spread in more indirect ways. Several 
studies have shown a higher presence of human carriers of antibiotic-resistant 
bacteria in areas near farms that use growth promoters in their animals.60 Stuart B. 
Levy, an expert in the field of antibiotic resistance, commissioned a study to test this 
                                                          
 52 See id. at 142.  
 53 See id. at 143.  
 54 See id. at 148150. In 2011, two separate Salmonella outbreaks led to massive food 
recalls, one of ground turkey originating from the Cargill Meat Solutions Corporation in 
Arkansas, and one of ground beef from a Maine based grocery store. The Salmonella strains 
present in ground turkey were resistant to three antibiotics including tetracycline and the 
ground beef strain was resistant to at least four different antibiotics. Multistate Outbreak of 
Human Salmonella Heidelberg Infections Linked to Ground Turkey, CTRS. FOR DISEASE 
CONTROL & PREVENTION ONLINE NEWSROOM, http://www.cdc.gov/SALMONELLA/ 
HEIDELBERG/111011/INDEX.HTML (last visited Jun. 24, 2014); Multistate Outbreak of 
Human Salmonella Typhimurium Infections Linked to Ground Ground Beef, CTRS. FOR 
DISEASE CONTROL & PREVENTION ONLINE NEWSROOM, http://www.cdc.gov/ 
salmonella/typhimurium-groundbeef/122011/ (last visited Jun. 24, 2014). 
 55 See LEVY, supra note 13, at 15053. 
 56 See id. at 150. 
 57 See id.  
 58 See id. Salmonella outbreaks in four Midwestern states occurred when infected beef 
cattle were packed, sold, and consumed. A study by the Centers of Disease Control concluded 
that many people who ate infected meat were unaffected since the bacteria concentration was 
small. However, “[t]hose who were taking antibiotics to which the Salmonella were resistant   
. . . provided a perfect environment for the resistant strain to multiply, leading to over clinical 
disease.”  See id. at 152.  
 59 See id.  
 60 See id. at 14344. 
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phenomenon as far back as 1975.61 On a small family farm, Levy’s research team fed 
some chickens antibiotic-laced feed and fed other chickens feed without antibiotics.62 
Within forty-eight hours, the chickens given the antibiotic-laced feed began 
excreting tetracycline-resistant E. coli, and after three months the E. coli was also 
resistant to four other antibiotics.63 Moreover, the farm family began displaying an 
“increasing number of fecal E. coli resistant to multiple antibiotics.”64 Levy found 
this evidence demonstrative of the way bacteria can spread from food animals to the 
environment and other humans through manure.65 Bacteria in manure sink into the 
ground, and the ground water, and are transferred to humans through touch or 
consumption.66 Bacteria may also be transferred to farm workers through the 
workers’ mouth, nose, or throat when they come into contact with food animals.67 
These workers then spread the bacteria to other humans through day to day 
interactions.68 Once antibiotic-resistant bacteria develop in animals, they can easily 
be spread around a farm and into the general population, thereby posing a serious 
threat to human health.69 
C.  Costs of Factory Farms 
1.  Economic Costs 
Antibiotic resistance costs the American public billions of dollars per year.70 The 
spread of antibiotic-resistant bacteria seems inevitable when one considers the sheer 
amount of meat consumed by Americans. In 2007, the average American ate 273 
pounds of meat.71 In order to satisfy the demand for meat, 10.378 billion U.S. land 
animals were slaughtered for food that year—roughly twenty-five percent of all 
animals killed for food in the world.72 Although this number has decreased slightly 
                                                          
 61 Hearing Before the Subcomm. on Health of the U.S. House Committee on Energy and 
Commerce, 111th Cong. (2010) (statement of Dr. Stuart Levy, Distinguished Professor of 
Molecular Biology & Microbiology and of Medicine), available at  http://www.tufts.edu/med/ 
apua/policy/7.14.10.pdf. 
 62 Id. 
 63 Id. 
 64 Id. 
 65 Daily animal fecal excretions can be 5400 times greater than humans. This greatly 
increases the transmission of antibiotic-resistant bacteria from animals to the environment and 
humans. Although some antibiotic resistance is caused by human overuse of antibiotics, 
subtherapeutic use in animals can have a much larger effect. See LEVY, supra note 13, at 143. 
 66 See id. 
 67 See id. at 144.  
 68 See id. at 14445. 
 69 See id. at 14748. 
 70 Evelyn B. Pluhar, Meat and Morality: Alternatives to Factory Farming, 23 J. AGRIC. 
ENVTL. ETHICS 455, 456 (2010).    
 71 Id.  
 72 Id.  
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since 2007, in 2011 the average American consumed 185 pounds of chicken, turkey, 
pork and beef,73 proving that the American appetite for meat is still substantial.74 
This massive appetite, combined with an increase in antibiotic resistance, has been 
costly for the American public. 
Antibiotic resistance greatly increases healthcare costs due to longer hospital 
stays and the costs of alternative disease treatments.75 In 1998, the National 
Academy of Sciences Institute of Medicine noted that antibiotic-resistant bacteria 
increased US health care costs by a minimum of four to five billion dollars 
annually,76 while in 2009 the total health care cost of antibiotic-resistant infections 
was estimated to be over $20 billion annually.77 In contrast, eliminating 
antimicrobials would only cost each American five to ten dollars per year,78 thereby 
saving a total of 1.3 to 3.7 billion dollars annually.79 To further break down the cost, a 
2005 analysis found that a hospital stay was $6,000 to $10,000 more expensive for a 
person infected with a resistant bacterium as opposed to an antibiotic-susceptible 
                                                          
 73 Allison Aubrey, The Average American Ate (Literally) A Ton This Year, THE SALT (Dec. 
31, 2011, 7:39 AM), http://www.npr.org/blogs/thesalt/2011/12/31/144478009/the-average-
american-ate-literally-a-ton-this-year.  
 74 On average, each American consumes around 110 grams of protein a day, about twice 
the federal government’s recommended allowance; of that, about 75 grams come from animal 
protein. The recommended level is itself considered by many dietary experts to be higher than 
necessary. It’s likely that most of us would do well on around 30 grams of protein a day, 
virtually all of it from plant sources. See Mark Bittman, Rethinking the Meat-Guzzler, N.Y. 
TIMES (Jan. 27, 2008), http://www.nytimes.com/2008/01/27/ weekinreview/27bittman.html? 
pagewanted=all&_r=0; see also infra Part III(C) (arguing that even if eliminating the root 
cause of antibiotic resistance means meat prices will rise, Americans can combat those costs 
and be healthier by eating less meat.).    
 75 CTR. FOR DISEASE CONTROL AND PREVENTION, APPROPRIATE ANTIBIOTIC USE – SAVES 
LIVES, SAVES MONEY, MAKES SENSE (2010), available at http://www.cdc.gov/getsmart/ 
healthcare/resources/factsheets/pdf/antibiotic-use.pdf. 
 76 INFECTIOUS DISEASES SOC’Y OF AM., BAD BUGS, NO DRUGS: AS ANTIBIOTIC DISCOVERY 
STAGNATES A PUBLIC HEALTH CRISIS BREWS (2004), available at http://www.idsociety.org/ 
uploadedFiles/IDSA/Policy_and_Advocacy/Current_Topics_and_Issues/Antimicrobial_Resist
ance/10x20/Images/Bad%20Bugs%20no%20Drugs.pdf.    
 77 ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS, THE COST OF ANTIBIOTIC RESISTANCE 
TO U.S. FAMILIES AND THE HEALTH CARE SYSTEM (2010), available at http://www.tufts. 
edu/med/apua/consumers/personal_home_5_1451036133.pdf. 
 78 THE PEW COMM’N ON INDUS. FARM ANIMAL PRODUCTION, PUTTING MEAT ON THE TABLE: 
INDUSTRIAL FARM ANIMAL PRODUCTION IN AMERICA 10 (2008), available at http://www. 
ncifap.org/_images/PCIFAPFin.pdf. 
 79 The U.S. population in 1999 was 272,690,813 and the estimated cost per person of 
eliminating antimicrobials was $5 to $10 per person. Id.; POPULATION ESTIMATES PROGRAM, 
POPULATION DIVISION, U.S. CENSUS BUREAU, ST-99-1, STATE POPULATION ESTIMATES AND 
DEMOGRAPHIC COMPONENTS OF POPULATION CHANGE:  JULY 1, 1998 TO JULY 1, 1999 (1999), 
http://www.census.gov/population/estimates/state/st-99-1.txt. Accordingly, the total cost of 
eliminating antimicrobials in 1999 was between $1.3 and $2.7 billion. This figure is $1.3$3.7 
billion less than the $4$5 billion antimicrobials raise costs by.  
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infection.80 Developing new antibiotics to replace those to which the new strands are 
resistant will require around ten years and an investment of $800 million to $1.7 
billion.81 
2.  Social Costs 
The greatest social cost is the suffering and death caused by antibiotic-resistant 
infections. Otherwise healthy adults and children can enter hospitals for routine 
procedures and die from MRSA and other antibiotic-resistant infections now 
prevalent in hospitals.82 In 2004, IDSA estimated that “[a]bout 2 million people 
acquire bacterial infections in U.S. hospitals each year and 90,000 die as a result.”83 
These diseases are even more dangerous to individuals with already compromised 
immune systems.84 Seventy percent of hospital-acquired infections are resistant to at 
least one antibiotic.85 When a patient has an antibiotic-resistant infection, hospital 
stays are extended by an average of 6.4 to 12.7 days.86 “During this time, patients are 
unable to work and . . . lose wages.”87 Increased hospital stays cost U.S. households 
over thirty-five billion dollars annually in the form of lost wages.88 The increased 
prevalence of antibiotic-resistant infections can transform hospitals, the places 
individuals go for health treatments, into heath threats due to the presence of MRSA 
and other infections. 
In addition to their negative effects on human health, factory farms have a 
negative impact on the environment and make life unpleasant for the animals 
themselves. “Globally, greenhouse gas emissions from all livestock operations 
account for 18% of anthropogenic greenhouse gas emissions, exceeding those from 
the transportation sector.”89 Massive amounts of greenhouse gases are created due to 
improper management of animals, manure, and soil on factory farms.90 Moreover, 
the amount of waste produced by mass confinement is a problem in and of itself.91 
The waste must be disposed of properly, and over-fertilization of pastures can lead to 
                                                          
 80 Sara E. Cosgrove et al., The Impact of Methicillin Resistance in Staphylococcus Aureus 
Bacteremia on Patient Outcomes: Mortality, Length of Stay, and Hospital Charges, 26 
INFECTION CONTROL & HOSP. EPIDEMIOLOGY 166, 171 (2005).    
 81 See INFECTIOUS DISEASES SOC’Y OF AM., supra note 76, at 3. The report also notes the 
incentive for pharmaceutical companies to produce new, more lucrative drugs that treat 
chronic conditions as opposed to developing new, less lucrative, antibiotics. For example, 
“[i]n 2002, out of 89 new drugs, no new antibiotics were approved.” Id. at 5.    
 82 Id. at 5.   
 83 Id. at 5. 
 84 Id. at 13. 
 85 Id. at 3.    
 86 ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS, supra note 77, at 2.     
 87 Id.   
 88 Id. 
 89 PEW COMM’N ON INDUS. FARM ANIMAL PROD., supra note 78, at 27.   
 90 Id. 
 91 Id. at 23. 
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surface and ground water contamination with extra nutrients, which the land cannot 
absorb.92 Water and other energy resources are also expended at a much higher rate 
on factory farms.93 These cramped and unsanitary conditions are particularly 
unpleasant for the animals, whose lives are truly unpleasant and short.94 Chickens are 
debeaked and declawed, and pigs are kept in small confinement crates and can drop 
dead from the stress of being confined.95 While cattle are generally allowed to graze 
freely, cattle raised for veal are fed a poor diet to stop certain types of development 
and placed in stalls too small for them to move in, hindering all muscle 
development.96 The substantial economic and social effects of factory farming and 
antibiotic resistance make the factory farming model unsustainable, costly, and 
detrimental to both human and animal health.97    
D.  Overview of Food and Drug Regulations 
While factory farming methods are not directly regulated, the federal government 
does play a role in regulating meat,98 milk,99 and eggs100 before they are consumed by 
Americans. These regulations have been strengthened over time, but are far from 
perfect. Federal regulation of food and drugs started with the signing of the Food and 
Drugs Act (Wiley Act) on June 30, 1906 by President Roosevelt.101 Administered by 
the Bureau of Chemistry under the federal commerce clause power,102 the Act 
prohibited the interstate transportation of unlawful food and drugs.103 The law sought 
                                                          
 92 Id. 
 93 Id. at 27, 29. Water resources are stressed by possible contamination and the sheer 
amount of water necessary to keep the animals hydrated. Id. at 27. Fossil fuels are also 
expended at a much higher rate along with industrial fertilizers and other synthetic chemicals. 
Id. at 29.   
 94 Barbra O’Brien, Comment, Animal Welfare Reform and the Magic Bullet: The Use and 
Misuse of Subtheraputic Doses of Antibiotics in Livestock, 67 U. COLO. L. REV. 407, 414–21 
(1996). 
 95 Id. at 41519. This is called porcine stress syndrome. Id. at 418–19. Pigs are stressed 
and confused by crowding and being ushered from pen to pen. Id. at 419. This can overwhelm 
the animals’ senses and lead them to bite the tails of other pigs or accidentally trample their 
own young. Id. at 418–19. 
 96 Id. at 42021.   
 97 See generally THE PEW COMM’N ON INDUS. FARM ANIMAL PROD., supra note 78. 
 98 7 C.F.R. pt. 54 (West 2014). 
 99 21 C.F.R. pt. 131 (West 2014).   
 100 7 C.F.R. pt. 57 (West 2014). 
 101 John P. Swann, FDA’s Origin, U.S. FOOD & DRUG ADMIN. (Jan. 23, 2014), http://www. 
fda.gov/AboutFDA/WhatWeDo/History/Origin/ucm124403.htm; see also FDA History - Part 
I: The 1906 Food and Drugs Act and Its Enforcement, U.S. FOOD & DRUG ADMIN. (June 18, 
2009), http://www.fda.gov/AboutFDA/WhatWeDo/History/Origin/ucm054819.htm; see also 
Federal Food and Drugs (Wiley) Act of 1906, Pub. L. No. 59-384, 34 Stat. 768 (repealed 
1938). 
 102 U.S. CONST. art. I, § 8, cl. 3; Wiley Act § 4. 
 103 FDA History - Part I, supra note 101.   
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to promote proper labeling and also prohibited the addition of any ingredients that 
would substitute for food, conceal damage, pose a health hazard, or constitute a 
filthy or decomposed substance.104 However, the head of the Bureau of Chemistry, 
Harvey Washington Wiley, often clashed with Secretary of Agriculture James 
Wilson due to Wiley’s skepticism of chemical additives.105 In an effort to undercut 
his administrative authority, Wilson created the Board of Food and Drug Inspection 
in 1907 to establish agency policy and enforce the law.106 During this time, Congress 
passed numerous other laws governing specific foods, and the Bureau of Chemistry 
developed many specific unofficial standards.107 This confusion made it difficult for 
manufacturers to comply and for the courts to know which standards to enforce.108 
1.  The Food, Drug, and Cosmetic Act 
The confusion over regulations left a clear need for legally mandated, specific, 
and uniform standards. This gap was filled by the Federal Food, Drug, and Cosmetic 
Act (FFDCA) enacted in 1938. The FFDCA gave the U.S. Food and Drug 
Administration (FDA) the authority to oversee the safety of food, drugs, and 
cosmetics.109 The FFDCA sought to fix the shortcomings of the Wiley Act by 
meeting the need for legally mandated quality and identity standards for foods and 
by expanding the authority to regulate false claims.110 The FFDCA helped prevent 
harmful drugs from entering the market by mandating pre-market approval of all 
drugs and formally authorizing factory inspections.111 Additionally, the Act provided 
the FDA with injunctive abilities and enforcement tools.112 
Since its passage, the FFDCA has been supplemented by several amendments. 
The 1958 Food Additives Amendment expanded the FDA’s regulatory authority 
over animal food additives and drug residues in animal-derived foods.113 Under the 
                                                          
 104 See id.    
 105 See id.    
 106 Id.    
 107 Id.    
 108 Id.    
 109 FDA History - Part II: The 1938 Food, Drug, and Cosmetic Act, U.S. FOOD & DRUG 
ADMIN. (Sept. 24, 2012), http://www.fda.gov/AboutFDA/WhatWeDo/History/Origin/ 
ucm054826.htm; see also Federal Food, Drug, and Cosmetic Act § 1, 21 U.S.C.A. § 301 
(West 2014). 
 110 See FDA History - Part II, supra note 109.   
 111 Id.    
 112 Id.    
 113 The term “food additive” is defined in 21 U.S.C.A. § 321(s) (West 2014), in pertinent 
part, as follows:   
any substance the intended use of which results or may reasonably be expected to 
result, directly or indirectly, in its becoming a component or otherwise affecting the 
characteristics of any food . . . if such substance is not generally recognized, among 
experts qualified by scientific training and experience to evaluate its safety, as having 
been adequately shown through scientific procedures (or, in the case of a substance 
used in food prior to January 1, 1958, through either scientific procedures or 
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Food Additives Amendment, drugs used in feed were considered additives.114 “The 
Animal Drug Amendments of 1968 combined veterinary drugs and additives into a 
unified approval process under the authority of the Bureau of Animal Drugs in the 
FDA”115 The DES proviso of 1962 was a step backwards for food policy, permitting 
the use of possible carcinogens in food animals as long as residues did not remain in 
edible tissues.116 As determining that no residue remained in tissues proved 
impossible, the provision was amended to allow for an “insignificant amount of 
                                                          
experience based on common use in food) to be safe under the conditions of its 
intended use; except that such term does not include . . .  a new animal drug. 
 
21 U.S.C.A. § 321(s) (West 2014). 
 114 FDA History - Part IV: Regulating Cosmetics, Devices, and Veterinary Medicine After 
1938, U.S. FOOD & DRUG ADMIN. (June 18, 2009), http://www.fda.gov/AboutFDA/ 
WhatWeDo/History/Origin/ucm055137.htm.   
 115 Id.; see also Animal Drug Amendments of 1968, Pub. L. No. 90-399, § 101, 82 Stat. 
342, 343; 21 U.S.C.A. § 348 (West 2014). The 1968 Animal Drug amendments were “the 
product of the work over four sessions of Congress of interested industry groups representing 
manufacturers and feed mill operators, veterinarians, and the [FDA].  It provides not only 
benefits for industry, but through improved procedures, benefits for the consumer in the more 
efficient and less costly production of [food].”  H.R. REP. NO. 90-875, at 119 (1967); see also 
21 U.S.C.A. § 360b (West 2014); Minor Use and Minor Species Animal Health Act of 2004, 
Pub. L. No. 108-282, 118 Stat. 891. 
 116 See FDA History - Part IV, supra note 114. The F.D.C.A. contains three anticancer 
(Delaney) clauses: 21 U.S.C.A. § 348(c)(3)(A) (West 2014); 21 U.S.C.A. § 360b(d)(1)(I) 
(West 2014); 21 U.S.C.A. § 379e(b)(5)(B) (West 2014). The Federal Register describes the 
changes in the DES proviso as follows:  
each clause also contains an exception, termed the “Diethylstilbestrol (DES) Proviso,” 
that permits administration of such substances to food-producing animals where: (1) 
The food additive, color additive, or new animal drug will not adversely affect the 
animal and (2) no residue of the food additive, color additive, or new animal drug will 
be found in any edible portion of that animal by a method of examination prescribed 
or approved by the Secretary of Health and Human Services by regulation . . . . So is 
currently defined as the concentration of the compound of carcinogenic concern in the 
total diet of test animals that corresponds to a maximum lifetime risk of cancer to the 
test animals of 1 in 1 million . . . FDA will assume that the So corresponds to the 
concentration of residue of carcinogenic concern in the total human diet that 
represents no significant increase in the risk of cancer to people.  The concentration, 
derived from the So, of residues of carcinogenic concern in a specific edible tissue is 
termed the Sm. This rule changes the definition of So so that it is primarily defined as 
“the concentration of a residue of carcinogenic concern in the total human diet that 
represents no significant increase in the risk of cancer to the human consumer . . .” 
and secondarily as “the concentration of test compound in the total diet of test animals 
that corresponds to a maximum lifetime risk of cancer in the test animals of 1 in 1 
million.”  The change in this rule to the definition of So is intended to enable the 
Center for Veterinary Medicine to consider allowing the use of alternative procedures 
to satisfy the DES Proviso without requiring the development of a second, alternative, 
set of terminology. 
Regulation of Carcinogenic Compounds in Food-Producing Animals, 77 Fed. Reg. 50,591 
(Aug. 22, 2012) (citation omitted) (to be codified at 21 C.F.R. pt. 500).   
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residue.”117 The FDA has discretion to prohibit the use of an additive if there is no 
reliable method to measure and confirm whether the additive contains carcinogenic 
residues at or above the no residue level.118 These requirements were further 
broadened in 2012.119 
The Food Safety Modernization Act (FSMA),120 signed into law by President 
Obama on January 4, 2011,121 constitutes the most recent expansion of FDA powers. 
The law institutes sweeping reform and aims to ensure a safe food supply by shifting 
the focus from contamination response to contamination prevention.122 The FSMA 
provides the FDA with additional enforcement authority to promote compliance 
before problems occur and to more effectively respond to them when they do.123 The 
law also directs the FDA to build an integrated national food safety system in 
partnership with state and local authorities and puts more responsibility on food 
producers to institute plans to make food safer.124 FSMA provides the FDA with 
additional enforcement and prevention tools which, if properly utilized, could 
improve food safety. 
2.  The Food and Drug Administration 
The FDA is charged with broad responsibility to regulate food, drugs, and 
cosmetics. The FDA is an executive agency within the Department of Health and 
Human Services at the same administrative level as the Center for Disease Control 
(CDC) and National Institute of Health (NIH).125 The Agency plays a regulatory and 
policy role in promoting the public health by ensuring that “foods are safe, 
wholesome, sanitary and properly labeled,” and that “human and veterinary drugs 
are safe and effective.”126 In addition to drugs used on humans, the FDA has a role in 
regulating drugs used in food animals before the animals are consumed.127 
Additionally, the Agency protects the financial interests of consumers by keeping 
                                                          
 117 Regulation of Carcinogenic Compounds in Food-Producing Animals, 77 Fed. Reg. at 
50,591. 
 118 Id.   
 119 Id.  
 120 Food Safety Modernization Act, 21 U.S.C. §§ 111353 (West 2012).   
 121 Id.  
 122 Food Safety Legislation Key Facts, FOOD & DRUG ADMIN., http://www.fda.gov/ 
downloads/Food/GuidanceRegulation/UCM263777.pdf (last visited April 16, 2014). 
 123 Id.  
 124 Id.   
 125 HHS Organizational Chart, DEP’T OF HEALTH & HUMAN SERVICES, http://www.hhs.gov/ 
about/orgchart/#text (last visited April 16, 2014).  
 126 Food and Drug Administration, 21 U.S.C.S. § 393 (West 2012).   
 127 About the Center for Veterinary Medicine, FOOD & DRUG ADMIN., http://www.fda.gov/ 
AboutFDA/CentersOffices/OfficeofFoods/CVM/default.htm (last visited April 16, 2014).  
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food and drugs reasonably priced and readily available.128 While the Agency has 
consistently relied on prevention and industry guidance, rather than periodic 
prosecutions, to promote health, legal and equitable remedies can be enforced both 
internally and through the courts.129 Outsiders may also propose FDA regulatory 
action, which can be adopted or rejected.130 The FDA’s role in food policy and its 
power to enforce compliance have steadily expanded since the Agency’s creation. 
III.  ARGUMENT 
A.  Current Laws 
The authority to regulate animal feed and food animals is spread between the 
states, Congress, and several executive agencies. The manufacturing of animal feed 
is regulated by both state and federal agencies.131 FDA inspectors have authority 
under the FFDCA to inspect the facilities of feed manufactures or to contract 
inspection duties out to state agencies, which conduct inspections in accordance with 
FDA procedures.132 All animal feed that contains a new animal drug is regulated by 
the FDA through the issuance of feed mill licenses.133 The Animal Drug User Fee 
Act authorizes the FDA to collect fees for animal drug applications and other 
services and to channel those funds to collect information about antimicrobial drug 
use.134 The Act also requires antimicrobial drug sponsors to self-report the amount of 
drugs sold annually and to provide the public with a copy of the report.135 
                                                          
 128 “The FFDCA and its legislative history make it clear that Congress intended the statute 
to protect the financial interests of consumers as well as their health.” See United States v. 
Lane Labs, 427 F.3d 219 (3rd Cir. 2005). 
 129 See, e.g., Current Good Manufacturing Practices for Finished Pharmaceuticals 21 
C.F.R. § 211 (West 2012); see also 21 U.S.C.A. § 360b (West 2012). FDA regulations focus 
on preventing unsafe drugs from entering the market through a mandatory approval process 
and good manufacturing practice recommendations, which help inform manufacturers of 
minimum standards which must be met before a drug can enter the market.   
 130 If an idea originates outside the FDA, it must get a sponsor within the FDA or a petition 
must be initiated, which can be filed by any person. 21 C.F.R. § 10.30 (West 2012). The FDA 
may call for specific adoption of a draft proposal by the Agency in the form of a proposed 
regulation. The regulation is circulated within the Agency and, if classed as “significant,” the 
FDA is required by the order to examine alternatives, study future cost consequences, and 
otherwise prepare itself to justify the proposed regulatory actions. Id.  
 131 There are several types of animal feed manufacturers. Feed mills are plants that 
combine ingredients, which may or may not include antibiotics, to produce an appropriate mix 
for a particular age or species of animal. There are operations that feed ruminant animals, 
rendering plants which process animals unfit for human consumption, and protein blenders 
who blend processed animal and vegetable protein. While the FDA is responsible for 
overseeing these manufacturers, states often have added regulations. GENERAL ACCOUNTING 
OFFICE, GOV’T ACCOUNTABILITY OFFICE, GAO/RCED-00-255, FOOD SAFETY: CONTROLS CAN 
BE STRENGTHENED TO REDUCE THE RISK OF DISEASE LINKED TO UNSAFE ANIMAL FEED (2000), 
available at http://www.gao.gov/new.items/rc00255.pdf.  
 132 Id. at 67. 
 133 Id. at 6.   
 134 Animal Drug User Fee Act of 2003, Pub. L. No. 108-130, 117 Stat. 1361; see also, 
Animal Drug User Fee Program – Revision and Extension, Pub. L. No. 110-316, 122 Stat. 
3509; see also, ADUFA Law, FOOD & DRUG ADMIN., http://www.fda.gov/ForIndustry/User 
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Several other executive agencies also play a role in the regulation of animal feed. 
The Environmental Protection Agency sets legal limits on the amount of pesticide 
residue in or on animal feed, and the FDA enforces these limits.136 The Department 
of Transportation regulates the transportation of animal feed, and the United States 
Department of Agriculture’s Animal and Plant Health Inspection Service regulates 
the health and care of food animals.137 Finally, the CDC is charged with monitoring, 
investigating, controlling, and preventing public health problems.138 
Within the FDA, the Center for Veterinary Medicine (CVM) ensures that animal 
drugs and medicated feeds are safe and effective for their intended uses and that food 
from treated animals is safe for human consumption.139 The CVM approves new 
animal drugs which have been shown to be safe and monitors drug use through 
surveillance and compliance programs.140 Animal feed must be “pure and 
                                                          
Fees/AnimalDrugUserFeeActADUFA/ucm042890.htm (last visited Jan. 26, 2013). ADUFA 
was originally passed in 2003 and was renewed on August 14, 2008 by President Bush.  As 
the FDA explains: 
[t]he new amendments extend ADUFA until 2013.  ADUFA amends the Food, Drug 
and Cosmetic Act to authorize FDA to collect fees to enhance the performance of the 
new animal drug review process and ensure that new animal drug products are safe 
and effective for animals as well as for the public with respect to animals intended for 
food consumption . . . .  In addition, this reauthorization encourages increased 
communications between FDA and industry, and also provides for improvements to 
the information technology infrastructure of animal drug review, providing a tool 
which enables industry to submit drug applications electronically and gives reviewers 
the ability to evaluate those applications online.  The reauthorization of ADUFA will 
generate $98 million in user fees over five years (FY 2009 – FY 2013). 
Id.  
 135 See ADUFA Law, supra note 134. 
 136 See GOV’T ACCOUNTABILITY OFFICE, supra note 131; see also 21 U.S.C.A. § 346a 
(West 2013). 
 137 See GOV’T ACCOUNTABILITY OFFICE, supra note 131. The U.S.D.A. is also responsible 
“for improving agricultural productivity while contributing to the nation’s economy and 
public health.” Id.  
 138 Id.   
 139 See FOOD & DRUG ADMIN., supra note 127.   
 140 The United States General Accounting Office has written a memo pointing out some of 
the shortcomings with these current regulations. The memo states, in pertinent part: 
FDA has taken some actions to better ensure the safety of animal feed, but problems 
such as lack of awareness of FDA’s regulation, delays in issuing a new FDA 
regulation to strengthen controls over the bacterial contamination of feed, and the 
Department of Transportation’s failure to issue regulations for the safe transport of 
animal feed, could lead to human illnesses. In 1997, FDA issued a regulation to 
prevent BSE [(mad cow disease)] in the United States. To assess compliance with this 
regulation, FDA and state inspectors have visited over 9,100 firms . . .  nearly 1,700 
firms were not aware of the regulation and thus could produce or use animal feed that 
was not in compliance. 
See GOV’T ACCOUNTABILITY OFFICE, supra note 131. 
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wholesome, produced under sanitary conditions, truthfully labeled, without any 
harmful substances.”141 The CVM has worked closely with the interagency Task 
Force on Antimicrobial Resistance, composed of representatives from the FDA, the 
CDC, and the NIH,142 to research antibiotic resistance, monitor antibiotic 
resistance,143 and develop industry guidances.144 However, these studies have not 
been translated into action. 
B.  Shortcomings of Current Food Policy 
1.  Limits of FDA Action 
The FDA is an executive administrative agency that shares powers with, and may 
be regulated by, all three branches of the federal government, as well as the 
Administrative Procedures Act (APA).145 As an executive agency, the FDA was 
created by an enabling act of Congress146 and may make rules regulating food and 
drugs within the scope of authority delegated.147 It is subject to legislative oversight 
and often has to answer tough questions from Congress and consider Congress’s 
recommendations.148 In addition to its legislative role, the FDA is an executive 
agency with the power to enforce compliance within its field, subject to presidential 
oversight.149 Although the FDA possesses some internal judicial power, almost all 
administrative agency procedures are subject to review by the federal courts.150 In 
                                                          
 141 FDA Related Laws, Regulations, and Guidances, FOOD & DRUG ADMIN., http://www. 
fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ucm052866.htm (last 
visited April 16, 2014).  
 142 ROSEANN B. TERMINI, FOOD AND DRUG LAW: FEDERAL REGULATION OF DRUGS, 
BIOLOGICS, MEDICAL DEVICES, FOODS, DIETARY SUPPLEMENTS, COSMETICS, VETERINARY AND 
TOBACCO PRODUCTS 17 (5th ed. 2012). 
 143 The taskforce monitored antimicrobial resistance through the National Antimicrobial 
Resistance Monitoring System (NARMS).  NARMS monitors trends in antibiotic resistance, 
targeting key bacteria such as Salmonella and E. coli. The Agency gathers animals isolated 
from a variety of sources around the country and tests for antimicrobial resistance and then 
reports on their findings. NARMS Program, FOOD & DRUG ADMIN. (Sept. 8, 2010), 
http://www.FDA.gov/AnimalVeterinary/SafetyHealth/AntimicrobialResistance/ 
NationalAntimicrobialResistanceMonitoringSystem/ucm059089.htm.   
 144 See TERMINI, supra note 142.  
 145 Id. (Administrative agencies are sometimes called the fourth branch of government due 
to their excessive power and limited direct supervision.).  
 146 The ceding of legislative rulemaking authority to an executive branch is justified under 
the Necessary and Proper Clause to ensure that food and drugs which are within interstate 
commerce are appropriately regulated. See U.S. CONST. art 1, § 8. Congress delegates this 
authority to the FDA through an enabling act.  21 U.S.C.A. 393b. 
 147 See TERMINI, supra note 142, at 24.    
 148 See id. at 22. 
 149 Id. at 21. 
 150 Id. at 21. 
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addition to case law, executive review, and congressional review, the FDA is 
governed by the APA, which has standardized procedures agencies must follow.151 
Congressional overview has had a detrimental effect on the FDA’s formation of 
new animal feed policy. In 1977, the FDA announced its intent to withdraw approval 
of the use of certain antibiotics for growth promotion and feed efficiency, noting that 
such practices are detrimental to human health.152 The FDA issued legal notices of 
hearings, giving the public the opportunity to prove that the drugs were in fact 
safe.153 However, no hearings or further action resulted, despite citizen petitions 
urging the Agency to follow through.154 This abrupt shift in momentum was likely 
due to congressional pressure. During the 1970’s and 1980’s, congressional 
committees issued three reports which the FDA interpreted as requests to postpone 
the withdrawal hearings pending further research.155 In response to these requests, 
the FDA commissioned more research instead of moving forward with hearings.156 
While the FDA has never said they postponed the hearings due to congressional 
requests, the FDA’s dependence on Congressional funding, along with its reliance 
on Congress as a source of authority, provides a strong motive to take Congress’s 
wishes into account.157 The sequence of events suggests that congressional oversight 
has hindered, rather than supported, FDA policy. 
Since 1977, the FDA has refused to take a firm stance on subtherapeutic 
antibiotic use, issuing interpretive rules on usage instead of substantive legally 
binding rules.158 Executive agencies create three types of rules: substantive, 
                                                          
 151 Id. at 18. 
 152 Natural Res. Def. Council, Inc. v. U.S. Food & Drug Admin., 884 F. Supp. 2d 127, 132 
(S.D.N.Y. 2012). The determination to withdraw approval was based upon the 
recommendations of a 1970 commission composed of members of the FDA, NIH, U.S. Dept. 
of Agriculture, and CDC, as well as industry members. In 1972, the task force concluded that: 
(1) subtherapeutic antibiotic use in animal feed favors the development of antibiotic 
resistance, (2) animals can pass these bacteria on to humans, (3) the number of bacteria 
resistant to multiple antibiotics has increased due to subtherapeutic use, (4) antibiotic-resistant 
bacteria has been found in meat, and (5) “the prevalence of antibiotic resistant bacteria in 
humans has increased.” Id. The commission recommended “antibiotics used in human 
medicine be prohibited from use in animal feed unless they met safety criteria established by 
the FDA and several specific drugs, including penicillin and tetracclines, be reserved for 
therapeutic use . . . .” Id. at 13233. 
 153 Id. 
 154 Id.  
 155 Id.  
 156 Id.  
 157 See TERMINI, supra note 142, at 22. Not only does Congress hold the “power of the 
purse” but they can also define the scope of the Agency’s power through legislation. Id. 
Added complications arise as the FDA is one department within the Department of Health and 
Human Services and requests for additional funds must go through the department 
bureaucracy and the Office of Management and Budget. Id.  
 158 Natural Res. Def. Council, Inc. v. U.S. Food & Drug Admin., 884 F. Supp. 2d 127, 132 
(S.D.N.Y. 2012).  
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interpretive, and procedural.159 Substantive rules are legally binding and enforceable 
regulations which define “the legal obligations and rights of those who are subject to 
the agencies authority.”160 In contrast, interpretive rules have no binding legal effect 
and are merely suggestions to the industry.161 Instead of creating legally binding 
substantive rules, the FDA has issued a number of Guidances, a type of interpretive 
rule.162 Guidance for Industry #152 discusses a recommended approach for assessing 
the safety of antimicrobial new animal drugs.163 The Guidance reaffirms the FDA’s 
belief that human exposure to antibiotic-resistant bacteria is harmful to human health 
and recommends that producers consider such risks when using antimicrobials.164 
However, the Guidance does not create any legally binding responsibilities or 
recommendations, and explicitly states that it “describes the Agency’s current 
thinking on the topic and should be viewed only as guidance, unless specific 
regulatory or statutory requirements are cited.”165 Likewise, Guidance for the 
                                                          
 159 Procedural rules are largely defined in the A.P.A. to promote uniformity among 
executive agencies and will be further discussed in the next subsection.  See NRDC, infra Part 
III(B)(2).  
 160 See TERMINI, supra note 142, at 19. 
 161 See id.at 19. 
 162 U.S. FOOD & DRUG ADMIN., GUIDANCE FOR THE INDUSTRY #152: EVALUATING THE 
SAFETY OF ANTIMICROBIAL NEW ANIMAL DRUGS WITH REGARD TO THEIR MICROBIOLOGICAL 
EFFECTS ON BACTERIA OF HUMAN HEALTH CONCERN (2003), available at http://www.fda.gov/ 
downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/ucm05
2519.pdf. The guidance contains a clear disclaimer which reads as follows: 
This guidance represents the Food and Drug Administration’s (FDA’s) current 
thinking on this topic.  It does not create or confer any rights for or on any person and 
does not operate to bind FDA or the public.  You can use an alternative approach if 
the approach satisfies the requirements of the applicable statute and regulations.  If 
you want to discuss an alternative approach, contact the FDA staff responsible for 
implementing the guidance.  If you cannot identify the appropriate staff, call the 
appropriate number listed on the title page of this guidance. 
 
Id. 
 163 Id.   
 164 Id. The guidance ranks certain antimicrobial agents by their importance to human 
medicine and asks that the critically important antimicrobials be used less frequently. The 
FDA also provides the following summary of the guidance: 
FDA recommends that sponsors choosing to use this process:  
• Prepare a hazard characterization (described in pages 7 through 8) and submit the 
characterization to the FDA for review.  
• After review of the hazard characterization, FDA and the sponsor may discuss 
whether a risk assessment needs to be completed and, if so, what information is 
recommended for completion of the risk assessment.   
• Prepare the risk assessment and submit the assessment to the FDA for review.  
• Following review of the safety package as a whole, including the risk assessment, 
FDA will determine the risk estimation and associated risk management steps 
applicable to the proposed conditions of use for the antimicrobial new animal drug.     
 165 Id. (The use of the word “should” in Agency guidance means that something is 
suggested or recommended, but not required). 
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Industry #209 explains the importance of the judicious use of antimicrobials, even 
going so far as to state “the use of medically important antimicrobial drugs in food-
producing animals should be limited to those uses that are considered necessary for 
animal health.”166 This Guidance lacks legal authority and leaves room for loopholes. 
For example, a farmer could simply state that subtherapeutic use was medically 
necessary.167 The fact that the food animal industry has largely ignored these 
Guidances, without any legal consequences, makes the need for binding substantive 
rules to combat antibiotic resistance apparent. 
2.  National Resources Defense Council v. Food and Drug Administration 
One court recently attempted to force the FDA to take action by enforcing 
procedural rules.168 In May 2011, the Natural Resources Defense Council (NRDC) 
filed a citizen petition seeking a court order to compel the FDA to follow through on 
the proceedings it initiated in 1977.169 The court considered (1) whether the FDA 
was legally required to act and (2) whether the court could legally compel them to 
act.170 The APA authorizes suits by “a person suffering legal wrong because of 
agency action, or adversely affected or aggrieved by agency action within the 
meaning of the relevant statute.”171 Reviewing courts can compel agency action 
unlawfully withheld or unreasonably delayed under this provision if the action was a 
discrete action that the Agency was legally required to take.172 The United States 
District Court for the Southern District of New York granted the plaintiffs’ motion 
for summary judgment and held that, pursuant to 21 U.S.C. 360b(e)(1), once the 
FDA found that the subtherapeutic use of penicillin and tetracyclines in animal feed 
was unsafe to humans, the Agency was statutorily obligated to withdraw approval of 
those uses unless drug sponsors demonstrated the safety of those drugs.173 
                                                          
 166 See GUIDANCE #209, supra note 7. 
 167 Id. A firm definition of what constitutes subtherapeutic use could help to close some of 
these loopholes, although the FDA and the courts will likely play a role in determining if use 
is medically necessary, on a case-by-case basis.    
 168 Natural Res. Def. Council, Inc. v. U.S. Food & Drug Admin., 884 F. Supp. 2d 127 
(S.D.N.Y.  2012). 
 169 Id. at 137. 
 170 Id. at 13738. 
 171 Id. at 131; see also, 5 U.S.C.A § 702 (West, 2014); Norton v. S. Utah Wilderness 
Alliance, 542 U.S. 55, 61 (2004).   
 172 NRDC, 884 F. Supp. 2d at 13840. Limiting court review to discrete actions serves an 
important policy purpose as it “‘precludes a court from authorizing ‘broad programmatic 
attack[s]’” on agency policy, and the limit to legally required actions ensures that a court will 
not interfere with an agency's discretionary functions. Id. (quoting SUWA, 542 U.S. at 
6465). Here, the court found that once an animal drug was deemed unsafe, several discrete 
actions were required including issuing notice of intent to withdraw approval, announcing the 
opportunity for hearing, holding a hearing, and finally withdrawing approval. 
 173 Id. at 151.   
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The 1977 withdrawal procedures were initiated based on the FDA’s findings that 
the use of certain drugs was unsafe for humans pursuant to 21 U.S.C. 360b(e)(1).174 
Guidance #152 and Guidance #209 described the serious health threat that 
antimicrobials pose and suggested non-binding recommendations for combatting 
antibiotic resistance.175 Accordingly, the FDA issued a proposal to withdraw 
approval of subtherapeutic use in animal feed unless data was submitted within the 
next two years which conclusively proved use was not a threat to human health.176 
Over the next two years, the CVM reviewed evidence submitted by interested parties 
and recommended continuing withdrawal procedures for subtherapeutic use of 
penicillin and tetracycline.177 The FDA then issued notice of withdrawal hearings 
and received twenty requests for hearings.178 The District Court ruled that once the 
CVM and the FDA followed procedures which proscribed clear and discrete actions 
for withdrawal of approval, the statutory language, “shall,” legally required the 
Secretary of Health to continue with the withdrawal proceedings, barring 
presentation of any important new information.179 Although the findings were 
                                                          
 174 Once the Secretary found the drug to be unsafe, withdrawing the drug was required 
unless new evidence emerged during the hearing.  21 U.S.C. 360, in pertinent part, reads as 
follows:  
the Secretary shall, after due notice and the opportunity for hearing to the applicant, 
issue an order withdrawing approval of an application . . . with respect to any new 
animal drug if the Secretary finds that . . . (B) that new evidence not contained in such 
application or not available to the Secretary until after such application was approved . 
. . evaluated together with evidence available to the Secretary when the application 
was approved shows that such drug is not shown to be safe for use under the 
conditions of use upon the basis of which the application was approved. 
21 U.S.C. 360. 
 175 GUIDANCE  #209, supra note 7; see also GUIDANCE #152, supra note 162.   
 176 NRDC, 884 F. Supp. 2d at 130.    
 177 Id. at 133. 
 178 Id. at 13334.   
 179  Id. at 141. The court relied on a plain reading of the text based on grammatical rules as 
described below: 
The “after due notice and opportunity for hearing” clause is setoff by commas and 
immediately precedes the words “issue an order withdrawing approval,” indicating 
that the “notice” clause modifies the “issue an order” clause and not the findings 
clause. See United States v. Liranzo, 729 F.Supp. 1012, 1014 (S.D.N.Y.1990) 
(interpreting a modifier to apply to the verb closest to it) (citing W. Strunk, Jr. & E.B. 
White, The Elements of Style 30 (3d ed. 1979)). Accordingly, the statute only requires 
the Secretary to give notice and provide an opportunity for a hearing before issuing an 
order of withdrawal and not before making findings.  Under this reading, if the 
Secretary finds that an animal drug has not been shown to be safe, he is statutorily 
required to withdraw approval of that drug, provided that the drug sponsor has notice 
and an opportunity for a hearing . . .  If, after a hearing, the drug sponsor has not met 
his burden of proving the drug to be safe, the Secretary must issue a withdrawal order. 
Id. at 14142; see also, Food & Drug Admin. v. Brown & Williamson Tobacco Corp., 529 
U.S. 120, 134 (2000) (“If the FDA discovers after approval that a drug is unsafe or ineffective, 
it ‘shall, after due notice and opportunity for hearing to the applicant, withdraw approval’ of 
 
2014]   COMBATTING ANTIBIOTIC-RESISTANT BACTERIA 281 
 
 
 
initiated by the Director of the CVM, and not the Secretary of the FDA, the Director 
was delegated the authority to make statutorily enforceable findings with the 
authority to issue notice of hearings.180 The CVM Director’s finding that the drugs 
were unsafe initiated a legally binding mandate to continue the withdrawal 
proceedings.181 
Accordingly, the court found that the FDA must re-issue a notice of the proposed 
withdrawals and provide an opportunity for a hearing to the relevant drug 
sponsors.182 If the drugs were not proven safe, approval must be withdrawn.183 There 
were several limitations on this ruling. The court stipulated the limitations of its 
holding, emphasizing that it was not ordering the FDA to ban the drugs outright, 
only to continue their mandated procedures.184 If the sponsors raised a substantial 
fact, the FDA must hold a public evidentiary hearing to determine if the sponsors 
could prove that the drug is safe.185 Otherwise, the Commissioners had to issue a 
withdrawal order.186 Additionally, the drugs at issue were only penicillin and 
tetracycline antibiotics, leaving many other medically important antibiotics on the 
market.187  
The N.R.D.C. filed a second suit against the FDA alleging a violation of the 
FDA’s procedural duty to take the citizen petitions seriously.188 Specifically, the 
NRDC alleged that the FDA violated section 706(2) of the Administrative 
Procedures Act, and section 360b(e) of the FFDCA, when it denied two citizen 
petitions requesting withdrawal of approval for subtherapeutic use of certain classes 
of antibiotics in food-producing animals.189 Both petitions provided credible 
scientific evidence to support their requests and both petitions received the same 
                                                          
the drug,”) (quoting 21 U.S.C. § 355(e)(1)-(3)); Mylan Lab., Inc. v. Thompson, 389 F.3d 
1272, 1281 (D.C. Cir. 2004)). 
 180 N.R.D.C., 884 F. Supp. 2d at 14546. While the statutory language is ambiguous, the 
court traced a clear path of delegation of authority from the Secretary of the Department of 
Health and Human Services, to the Commissioner of the FDA, to the Director of the BMV to 
issue notices. Id.      
 181 Id. 
 182 Id. at 151.   
 183 Id.  
 184 Id. Judge Katz emphasized the limitations that the court is not ordering a particular 
outcome, if the drug companies prove the drug is safe approval cannot be withdrawn. Id. 
 185 Id. 
 186 Id.  
 187 Id. at 13132.   
 188 Natural Res. Def. Council, Inc. v. U.S. Food & Drug Admin., 872 F. Supp. 2d 318, 321 
(S.D.N.Y. 2012). 
 189 The first petition was in 1999 and requested that “the agency ‘rescind approvals for 
subtherapeutic uses in livestock of any antibiotic used in (or related to those used in) human 
medicine’ . . . it named several specific classes of antibiotics for which it sought withdrawal, 
including penicillin, tetracyclines, erythromycin, lincomycin, tylosin,and virginiamycin.” The 
2005 petition made similar request.  Id. at 32426.  
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response from the FDA190 The FDA provided an initial response detailing the 
complex nature of the problem, detailing the FDA’s limited resources and the 
alternative means by which they were attempting to tackle the problem, and stating 
that withdrawal must be considered on a drug-by-drug basis.191 The FDA then 
proceeded to deny the requests based on the fact that no hearings had been held, 
based on the time and expense withdrawal would take, and based on the alternative 
strategy the FDA was pursuing.192 Under 5 U.S.C. § 706(2)(A), a court may set aside 
the FDA’s findings, conclusions of laws, or actions if they are “arbitrary, capricious, 
an abuse of discretion, or otherwise not in accordance with law.”193  
The FDA still prefers a voluntary phasing out of subtherapeutic use. The Agency 
appealed both rulings and motioned for a continuance to allow the industry time to 
comply.194 While the motion for a continuance was denied, both district court rulings 
were overruled in July 2014.195 The Second Circuit Court of Appeals found that 21 
U.S.C. § 360b(e)(1) was ambiguous, but ultimately agreed with the FDA: 
[t]he statute requires the FDA to withdraw approval of an animal drug 
only “after due notice and opportunity for hearing” has been afforded, and 
then only “if the Secretary finds” that the drug is not shown to be safe.  21 
                                                          
 190 Id.  
 191 Id. These alternative methods are far from satisfactory as they only involved issuing 
Guidances. Although the FDA’s plan seemed to be a step in the right direct they refused to 
mandate compliance and the industry had failed to self-regulate.  The court opinion provides, 
in pertinent part: 
Specifically, the FDA cited Draft Guidance # 209, entitled “The Judicious Use of 
Medically Important Antimicrobial Drugs in Food–Producing Animals,” which 
recommends limiting the use of antibiotics in food-producing animals to judicious 
uses.  Draft Guidance # 209 states that the FDA does not consider growth promotion 
or feed efficiency to be judicious uses. Draft Guidance # 209 also recommends that 
the use of medically-important antibiotics in food-producing animals should be 
limited to “uses that include veterinary oversight or consultation.”  The FDA 
explained that “[b]ased on feedback [the FDA] has received [regarding Draft 
Guidance # 209], FDA believes that the animal pharmaceutical industry is generally 
responsive to the prospect of working cooperatively with the Agency to implement the 
principles recommended in [the Draft Guidance].”  The FDA stated that it planned to 
phase-out over-the-counter use of medically-important antibiotics in animal feed and 
move to a veterinary feed directive (“VFD”) status for such drugs.  The FDA also 
stated that it planned to work cooperatively with industry to achieve this transition.  
“FDA believes that the strategy set out in draft guidance # 209 is a pathway to 
achieving the same goals as those advocated in [the 1999 Petition] . . . . ” 
Accordingly, the FDA refused to initiate withdrawal proceedings for the drugs 
included in the 1999 Petition. 
Id. at 326 
 192 Id. 
 193 5 U.S.C. § 706(2)(A) (West 2014).   
 194 Natural Res. Def. Council, Inc. v. U.S. Food & Drug Admin., 884 F. Supp. 2d 108 
(S.D.N.Y. 2012). 
195 Natural Res. Def. Council, Inc. v. U.S. Food & Drug Admin., 2d Cir. No. 12-2106-CV L, 
2014 WL 3636283 (July 24, 2014). 
2014]   COMBATTING ANTIBIOTIC-RESISTANT BACTERIA 283 
 
 
 
U.S.C. § 360B(e)(1). That language most naturally refers to a finding that 
is issued as a result of the hearing. That interpretation, moreover, avoids 
injecting a second, unexpressed “finding” into the sequence of events 
mentioned in the statute.196 
 
This holding means that withdrawal is only mandatory after manufacturers 
have had a hearing and, after hearing the evidence, the FDA finds that the drug 
is unsafe. Since the FDA did not issue a finding after conducting hearings, the 
Second Circuit granted summary judgment to the FDA. The court also found 
that the decision to ignore the citizen petitions was not arbitrary or 
capricious.197 The ruling was not unanimous, with Chief Judge Katzmann 
issuing a dissent vehemently opposing the majority opinion.198 
C.  Proposed Changes 
The economic and social costs of antibiotic resistance must be combated through 
congressionally mandated standards, mandatory FDA withdrawal of subtherapeutic 
antibiotic use in food animals, and enforcement through the courts. The District 
Court’s opinion illustrates the need for a joint effort by the courts, the FDA, and 
Congress to tackle the problem of antibiotic resistance.199 While the court found that 
the FDA had a legal obligation to follow the procedures dictated by Congress, the 
opinion also emphasized that policy making was not the proper sphere of the 
courts.200 When interpreting an ambiguous statute, the court must interpret 
congressional intent, and for further guidance, defer to the Agency’s interpretation, 
as long as such interpretation is reasonable—essentially allowing the court to act as a 
legislative or executive body.201 Even if the FDA had to fully comply with the court 
order, the ruling would have a limited effect—only approval for tetracyclines and 
penicillin would be withdrawn, allowing for subtherapeutic use of many other 
antibiotics.202 In light of these overlapping roles, Congress must pass legislation with 
                                                          
196 Id.  
197 Id.  
198 Id.  
 199 Natural Res. Def. Council, Inc. v. U.S. Food & Drug Admin., 884 F. Supp. 2d 127, 
14249 (S.D.N.Y. 2012). 
 200 Id. at 151. Courts, the district court noted, must provide appropriate oversight without 
telling the agency the best way to do their job:   
when an agency is compelled by law to act within a certain time period, but the 
manner of its action is left to the agency's discretion, a court can compel the agency to 
act, but has no power to specify what the action must be.”  The Court further 
explained that the purpose of the limitations under § 706(1) “is to protect agencies 
from undue judicial interference with their lawful discretion, and to avoid judicial 
entanglement in abstract policy disagreements which courts lack both expertise and 
information to resolve. 
Id. at 138 (quoting SUWA, 542 U.S. at 6566 (2004) (internal citations omitted)).   
 201 Id. at 141. 
 202 Id. at 151. 
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clear and concise definitions that makes elimination of subtherapeutic use a clear 
priority. This will create a clear mandate to combat the growing threat of antibiotic 
resistance that the FDA will execute and the courts will enforce, if necessary. The 
FDA should have broad autonomy to fulfill the legislative mandate as they see fit, 
except when there is a broad failure of mission. 
1.  Make Certain Standards Legally Binding Through Legislation 
To combat antibiotic resistance, legislation should be enacted to compliment the 
FDA’s efforts at eliminating harmful subtherapeutic antibiotic use. This legislation 
should include a three-tiered approach to battling antibiotic resistance in order to 
fulfill three goals: the immediate elimination of subtherapeutic use of medically 
important antibiotics, the complete phasing out of intensive confinement systems 
within ten years, and the eventual elimination of all subtherapeutic antibiotic use. 
The first phase of elimination entails defining and withdrawing approval of 
subtherapeutic use of all medically important antibiotics (those that are used to treat 
human illnesses). This phase should reinforce and expand upon the FDA’s 
withdrawal of approval for penicillin and tetracyclines. The second phase involves 
supplementing the Food Safety Modernization Act’s creation of state grants. Funds 
should be set aside for the FDA to administer to states, farms, or organizations that 
come up with creative or sustainable ways to eliminate all subtherapeutic use. 
Finally, the third phase requires the complete phasing out of intensive confinement 
systems and subtherapeutic antibiotic use within ten years of the Act’s passage. 
 
Phase 1: Define key terms and eliminate subtherapeutic use of medically 
important antimicrobials. 
 
The Preservation of Antibiotics for Medical Treatment Act of 2011 (PAMTA) 
should serve as a foundation for defining and withdrawing use of medically 
important subtherapeutic antibiotics.203 PAMTA was proposed to the House of 
Representatives Committee on Energy and Commerce as a supplement to the Food, 
Drug, and Cosmetic Act.204 Although this Act had very little support within the 
Committee, the passage of parts of PAMTA could still serve as the first phase of a 
comprehensive legislative effort to combat antibiotic resistance. The first step in 
regulating harmful antibiotics must be to create uniform and legally enforceable 
definitions. These uniform definitions should be adopted by all U.S. regulatory 
agencies. 
PAMTA procedures for withdrawing approval of all subtherapeutic use of 
medically important antimicrobials within two years should be enacted into law.205 In 
2009, eighty percent of all antibacterial drugs disseminated in the United States were 
                                                          
 203 See Preservation of Antibiotics for Medical Treatment Act of 2011 [hereinafter 
PAMTA], H.R. 965, 112th Cong. (2011). 
 204 Id. 
 205 Barbara O’Brien, recognizing the many barriers to change and government inaction, 
suggests an outright ban on all subtherapeutic uses as the most practical way to combat the 
problem of antibiotic resistance and animal cruelty. While total elimination must be the 
ultimate goal, it is impractical as the first step due to the industry’s dependence on such drugs. 
This Note seeks to build on that approach and suggest a multifaceted approach as opposed to 
an outright ban. See O’Brien, supra note 94, at 41214.  
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sold for use on food animals, and about eighty-four percent of farmers administered 
antimicrobials in food or water, many of which are closely related to human drugs.206 
The sheer number of drugs used for this purpose, along with many industry 
studies,207 shows that subtherapeutic use of the same antimicrobials in both humans 
and food animals is the most serious cause of antibiotic resistance in humans.208 
Switching from drugs used in humans to other antimicrobials should be mandated, 
especially as many alternative drugs that are not used in humans are readily 
available.209 
The FDA procedures for withdrawal of certain medically important 
antimicrobials are consistent with the PAMTA requirements. PAMTA requires the 
Secretary to withdraw approval of subtherapeutic use of medically important 
antimicrobials within two years, unless during that time it can be demonstrated that 
there is no harm to human health.210 Additionally, the Act forbids approval of any 
new medically important drugs for growth purposes unless there is reasonable 
certainty that there would not be harm to human health.211 Passing legislation that 
creates legally binding definitions and mandates procedures for withdrawing 
                                                          
 206 PAMTA, supra note 203, at § 2 (finding that, in 2009, “13.1 million kilograms of 
antibacterial drugs were sold for use on food animals in the United States . . . [only] 3.3 
million kilograms of antibacterial drugs were used for human health in 2009.”); see also Levy, 
supra note 13 at 140. 
 207 See Levy Testimony, supra note 61.   
 208 PAMTA, supra note 203, at 29.  Other studies have provided more direct evidence of 
the link between subtherapeutic use in animals and human antibiotic-resistant infections, and 
of meat products contaminated with antibiotic-resistant bacteria. See Levy Testimony, supra 
note 61 (citing several studies that confirm the impact food animals have an antibiotic 
resistance including one study that found antibiotics present in 48% of streams tested 
nationwide, half of which were downstream from agricultural operations).  
 209 Much of the beef industry has already self-regulated and switched to non-human 
antimicrobials upon the recommendation by the American Cattleman’s Association. 
Additionally, much of Europe has already mandated this switch. These swift and easy 
transitions prove that the entire industry could switch if required to do so.    
 210 PAMTA specifies: 
[t]he Secretary shall withdraw the approval of a nontherapeutic use in food producing 
animals described in paragraph (1) on the date that is 2 years after the date of 
enactment of this subsection unless- (A) before the date . . . the Secretary makes a 
final written determination that the holder of the approved application has 
demonstrated that there is a reasonable certainty of no harm to human health due to 
the development of antimicrobial resistance that is attributable in whole or in part to 
the non-therapeutic use of the drug . . .   
See PAMTA, supra note 203, § 4(q)(2). 
 211 Once legislation deems subtherapeutic use unsafe, the new policy could be instituted 
under the FDA’s current new drug approval process. 21 U.S.C.A. § 360(b) provides that new 
animal drugs shall be deemed unsafe, and thus denied approval, unless they conform to 
current laws and are shown to be safe for the public. This provision applies both to drugs 
administered directly to the animals, or indirectly through feed. PAMTA, supra note 203, at 
§ 4; 21. U.S.C.A. § 360(b) (West 2014) (delineating annual registration and approval 
requirements for drugs administered directly to animals, or indirectly through feed).        
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approval of subtherapeutic usage within two years of the Act’s passage is the first 
and most important step in fighting antibiotic resistance. Congress should adopt a 
statute substantially similar to the following model: 
 
DEFINITIONS - SECTION 201 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT 
(21 U.S.C. 321) IS AMENDED BY ADDING AT THE END THE FOLLOWING: 
1. ANTIMICROBIAL ANIMAL DRUG—The term “antimicrobial animal 
drug” means: A substance that is composed wholly or partly of any drug or 
derivative of a drug that is used in or intended for use in food-producing 
animals. 
2. MEDICALLY IMPORTANT ANTIMICROBIAL ANIMAL DRUG—The 
term “medically important antimicrobial animal drug” means: an 
antimicrobial animal drug that is used in humans or intended for use in 
humans to treat or   prevent   disease or infections caused by 
microorganisms.  
3. SUBTHERAPEUTIC USE—The term “subtherapeutic use” means:  The 
use of an antimicrobial in a food animal, in the absence of any clinical sign 
of disease or disease exposure in the animal for growth promotion, feed 
efficiency, weight gain, routine disease prevention or other routine purpose. 
4. INTENSIVE CONFINEMENT—The term “intensive confinement” means: 
any structure that would substantially restrict the natural movement and 
normal behaviors of an animal. 
 
ELIMINATION OF DRUGS IMPORTANT FOR HUMAN HEALTH 
1. APPLICABILITY—This subsection applies to the subtherapeutic use in 
a food-animals of a medically important antimicrobial animal drug.   
2. WITHDRAWAL—The Secretary shall withdraw the approval of a 
subtherapeutic use in food-animals described in paragraph (1) 2 years 
after the date of enactment of this subsection. 
3. APPROVALS —If an application for a drug that is a medically 
important antimicrobial animal drug is submitted to the Secretary under 
section 505(b), the Secretary shall rescind each approval of a 
nontherapeutic use in a food animal of the drug as of the date that is 2 
years after the date on which the application is submitted to the 
Secretary. 212 
                                                          
 212 These definitions are a combination of language from PAMTA and from the 
recommendation of the Pew Commission on Industrial Farm Animal production. PAMTA 
provides, in relevant part:  
(ss) CRITICAL ANTIMICROBIAL ANIMAL DRUG.— The term ‘critical antimicrobial 
animal drug’ means a drug that— 
          (1) is intended for use in food-producing animals; and  
          (2) is composed wholly or partly of—  
    (A) any kind of penicillin, tetracycline, macrolide, lincosamide,  
    streptogramin,  aminoglycoside, or sulfonamide; or  
    (B) any other drug or derivative of a drug that is used in humans or  
    intended for use in humans to treat or prevent disease or infection  
    caused by microorganisms. 
(tt) NONTHERAPEUTIC USE. — the term ‘nontherapeutic use’, with respect to a critical 
antimicrobial animal drug, means any use of the drug as a feed or water additive for 
an animal in the absence of any clinical sign of disease in the animal for growth 
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Phase 2: Create additional state grants to help farmers transition into total 
elimination of subtherapeutic antibiotic use. 
 
While withdrawing approval for the use of medically important antimicrobials is 
an important first step, total elimination of subtherapeutic use must be the end goal 
to fully eliminate the problem of antibiotic resistance. However, as our modern meat 
industry is built around the low cost and high volume of meat that factory farms can 
produce, legislation must be careful to consider the effects on the meat industry, as a 
whole, of eliminating intensive confinement systems.213 These systems must be 
phased out gradually so the industry has time to adjust.   
In order to make the process easier, the new legislation should immediately 
supplement the Food Safety Modernization Act’s creation of state grants. The FDA 
should receive grants to distribute to state governments, farms, or other entities that 
attempt to institute creative and sustainable models that eliminate intensive 
confinement systems or subtherapeutic antibiotic use. These subsidies provide an 
incentive for farmers to be innovative and start to move towards more sustainable 
practices.    
 
Phase 3: Eliminate intensive confinement systems factory farms and ban all 
subtherapeutic antibiotic usage. 
 
The eventual elimination of all intensive confinement systems must be legally 
mandated to slow the development of antibiotic-resistant bacteria. The new 
legislation should require the FDA to set the goal of eliminating all intensive 
confinement systems, those which restrict the natural movement and normal 
behaviors of animals,214 within ten years of the act’s passage. Although eliminating 
the use of medically important antibiotics for growth promotion is a key first step, it 
                                                          
promotion, feed efficiency, weight gain, routine disease prevention, or other routine 
purpose.   
 
PAMTA, supra note 203, § 4 (sstt). The Pew Commission suggests similar, but not 
identical, definitions in its report: 
a. The Commission defines as nontherapeutic any use of antimicrobials in 
food animals in the absence of microbial disease or known (documented) 
microbial disease exposure; thus, any use of the drug as an additive for 
growth promotion, feed efficiency, weight gain, routine disease prevention 
in the absence of documented exposure, or other routine purpose is 
considered nontherapeutic. 
b. The Commission defines as therapeutic the use of antimicrobials in 
food animals with diagnosed microbial disease.  
PEW COMM’N, supra note 78, at 63. I would not recommend listing specific types of drugs—as 
PAMTA does—because a basic rule of statutory interpretation indicates that listing some 
drugs seems to exclude other drugs; instead, the act can provide a dynamic definition that the 
courts can then interpret. See supra Section III(C)(3).   
 213 See supra Part II. 
 214 See PEW COMM’N, supra note 78, at 33. 
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is not alone sufficient to combat the threat of antibiotic resistance. When bacteria 
select, they can build up resistance to multiple antibiotics215 and, therefore, may still 
pose a threat in the future. Thus, a comprehensive plan must address the root cause 
of what makes subtherapeutic use necessary on the factory farm: close confinement. 
If animals were not kept in such close quarters, disease would not have the potential 
to quickly spread throughout the entire population.216 Additionally, smaller-scale 
farms could keep better records of the health of each individual animal and respond 
to outbreaks more efficiently.217 Once intensive confinement systems are eliminated, 
the subtherapeutic use of all antibiotics should be banned as well. The following 
statutory language should be added to the end of the proposed regulation in Part 
C(1)(a) of this Note: 
 
C.  ELIMINATION OF INTENSIVE CONFINEMENT SYSTEMS 
 1. APPLICABILITY—This subsection applies to the regulation of the 
intensive confinement of food-animals.     
 2.  WITHDRAWAL—All intensive confinement systems described in 
paragraph (1) shall be eliminated within 10 years after the date of the 
enactment of this subsection. 
 
D.  ELIMINATION OF SUBTHERAPEUTIC USE IN FOOD-ANIMALS. 
 1. APPLICABILITY—This subsection applies to the subtherapeutic use in a 
food-animals of an antimicrobial animal drug.   
 2.  WITHDRAWAL—The Secretary shall withdraw the approval of a 
subtherapeutic use in food-animals described in paragraph (1) 10 years after 
the date of enactment of this subsection. 
 3. APPROVALS —If an application for a drug that is an antimicrobial animal 
drug is submitted to the Secretary under section 505(b), the Secretary shall 
rescind each approval of a nontherapeutic use in a food animal of the drug, 
as of the date that is 2 years after the date on which the application was 
submitted to the Secretary. 
 
Outlawing intensive confinement systems will likely mean a decrease in 
efficiency, at least in the short term. Accordingly, production and prices would rise if 
intensive confinement systems were phased out (with the possible exception of beef 
which is less reliant on intensive confinement). This increase in prices is acceptable 
for several reasons. First, most Americans already eat more meat than ever before, 
and far more than the recommended daily amount.218 Even if higher prices meant 
less meat for consumers, health could be further enhanced by a reduction in meat 
eating.219 Moreover, as previously mentioned, the cost of antibiotic-resistant 
infections is massive. The rise in meat prices would be comparatively smaller and 
more manageable as the cost would be spread across all consumers.220 Many 
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individuals already pay a four to five dollar premium price for meat that is “free 
range,” “hormone free,” or “organic.”221 Over time, most individuals would find the 
additional cost manageable; low income households could receive assistance through 
government assistant programs which are already in place to combat hunger and 
malnutrition.222      
In addition, wealth would likely increase in rural areas which have been driven 
into poverty largely by the rise of the factory farming system. Citizens of rural areas 
generally have lower incomes due to less educational attainment, fewer 
opportunities, and less diversity.223 This problem is amplified by factory farms, 
which drive small family-owned farms out of business. Rural communities benefit 
from locally owned and controlled farms as, in addition to hiring locals to work on 
the farm, they tend to buy other services and supplies locally.224 This “multiplier 
effect” keeps approximately seven dollars by dollars earned on local farms in the 
community.225 Many large factory farms are vertically integrated with large 
suppliers, making their multiplier substantially lower.226 Additionally, “reduced civic 
participation rates, higher levels of stress, and other less tangible impacts have all 
been associated with high concentrations of industrial farm production.”227 Thus, 
although breaking up intensive confinement systems could increase the cost of meat, 
the economies of many rural areas would greatly benefit from this policy—as would 
the health of Americans, thereby offsetting some of the cost. 
2.  Develop Clear FDA Definitions and Guidelines 
The FDA should consult with industry experts, manufacturers, and veterinarians 
to convert Guidance #152 and Guidance #209 into binding minimum standards. The 
FDA must follow the withdrawal procedures and timetables dictated by Congress 
and can use industry Guidances to fill in the instructional gaps in legislation. While 
the Guidance letters are an excellent way to provide manufacturers with pertinent 
information, they must have some legal backing to ensure compliance.228 The 
Guidances should be converted from non-binding recommendations to binding 
industry standards. In addition to the immediate review of existing approvals, which 
must be withdrawn, the FDA should create a permanent schedule for reviewing 
existing approvals. In this way, the FDA could translate the congressional mandate 
for change into workable minimum standards based on a reasonable timetable.  
Total compliance must be phased in, and the FDA will likely not choose to 
prosecute all firms who fail to meet these guidelines during the first few years. Firms 
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should self-report how they met, or strived to meet, the good manufacturing 
practices guidelines, and report any problems they may have. If firms have not met 
these guidelines, they should have to submit a comprehensive plan on how to meet 
them in the future. Such a system allows the FDA to work with the industry towards 
voluntary compliance, as the FDA prefers, while also establishing clear goals and 
guidelines. 
3.  The Role of the Courts 
While the courts should generally defer to the FDA’s policy choices, they are 
still an important check on the Agency’s power and play a key role in enforcing drug 
regulations. The courts must walk a fine line between hindering the FDA’s policy-
making ability and giving the Agency free reign to do what it wishes.229 On the one 
hand, discretion allows the FDA to predict the outcome of rulemaking and extend its 
power based on assurance of judicial support. However, as the court articulated in 
American College of Neuropsychopharmacology v. Mathews, “[b]ureaucratic power 
in any agency seems to grow to fill whatever bounds are permitted it by Congress 
and the courts, and the courts do rein in the exuberant jurisdiction-extending 
agencies, when they determine that zeal has exceeded legal authority.”230 In the case 
of antibiotic resistance, the courts have recognized a serious threat to public health 
and have ordered the FDA to act accordingly. 231 The courts should continue to 
recognize the rights of citizens to petition the FDA to fulfill their regulatory 
responsibilities when such requests are backed by firm scientific foundations, but 
continue to filter out frivolous lawsuits. 
If the proposed legislation is passed, the courts will need to ensure that the FDA 
follows the law. Although the FDA can use their discretion in withdrawing use, they 
must determine which antibiotics are subject to removal.232 If a company disputes the 
legality of their antibiotic use, the court would have to interpret and apply the new 
law. The definition of “subtherapeutic” is based on whether or not the purpose of the 
drug use is to treat illness or promote growth, forcing the courts to look at key 
indicators to determine whether or not drug was intended for subtherapeutic use. 
However, the increase in legislation should not be substantial as many farmers may 
be hesitant to sue the FDA for fear of reprisals in their licensing actions, and the 
FDA rarely brings cases they are not sure they can win. Therefore, the courts should 
be sure to enforce the new legislation while being careful to grant the FDA sufficient 
discretion. 
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IV.  CONCLUSION 
The economic and social costs of antibiotic resistance must be combated through 
the joint efforts of Congress, executive agencies, and the courts using 
congressionally mandated standards, FDA approval withdrawal procedures, and the 
court system. Now, more than ever, scientists and government officials alike are 
recognizing the serious economic, social, and health costs created by antibiotic-
resistant bacteria.233 Antibiotic overuse has led to the creation of “superbugs” that are 
more difficult and costly to treat, and an increase in the prevalence of allergies, 
asthma, and autoimmune diseases.234 Current food and drug legislation does nothing 
to eliminate this threat, and the FDA has refused to provide clear, consistent, and 
binding guidelines to address the problem. A comprehensive, joint effort must be 
made by Congress, the FDA, other regulatory agencies, and the courts to eliminate 
the pervasive problem. The legislature must create legally binding standards that are 
easily followed by administrative agencies and enforced by the courts. At the same 
time, it must preserve the FDA’s discretion to implement such changes based on 
their expertise. Congress must create a uniform definition of subtherapeutic 
antibiotic usage, immediately mandate the withdrawal of approval of medically 
important antibiotics for subtherapeutic use, and eliminate all subtherapeutic use in 
the future. Such legislation will inevitably affect the price and quantity of meat 
produced. Therefore, these changes must be enacted in phases and special care 
should be taken to help ease the transition for farmers. While the public may be 
asked to pick up some of the cost increase, the amount saved in healthcare costs will 
lead to a net savings for the United States as a whole.   
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